E B O L A

[Aman A.K.A. Ahamburger]

This is.... interesting? Cooler With Ebola-tainted Blood Stolen in Guinea

[dothedd]

Ebola Deaths Near 5,500 As Virus Still Rages 

Fri, 2014-11-21 15:20 — Mike Kraft 

WALL STREET JOURNAL 

resiliencesystem.org/ebola-deaths-near-5500-virus-still-rages

[dothedd]

Nov 20, 2014 22:22:58 GMT -5 Aman A.K.A. Ahamburger said:

This is.... interesting? Cooler With Ebola-tainted Blood Stolen in Guinea

 Greetings, Aham .... 

I saw that article!   I thought while reading it that it would be an excellent method for spreading EBOLA around to uninfected areas like across the Texas/Mexico border

IT IS A VERY DANGEROUS WORLD!

b 

[dothedd]

EBOLA RESPONSE ROADMAP 

SITUATION REPORT UPDATE 

21 NOVEMBER 2014

apps.who.int/iris/bitstream/10665/144117/1/roadmapsitrep_21Nov2014_eng.pdf

[mmhmm]

Nov 21, 2014 16:42:26 GMT -5 dothedd said:

Nov 20, 2014 22:22:58 GMT -5 Aman A.K.A. Ahamburger said:

This is.... interesting? Cooler With Ebola-tainted Blood Stolen in Guinea

 Greetings, Aham .... 

I saw that article!   I thought while reading it that it would be an excellent method for spreading EBOLA around to uninfected areas like across the Texas/Mexico border

IT IS A VERY DANGEROUS WORLD!

b 

Actually, it wouldn't.  Long Article Well Worth a Read

[Aman A.K.A. Ahamburger]

Nov 21, 2014 16:42:26 GMT -5 dothedd said:

Nov 20, 2014 22:22:58 GMT -5 Aman A.K.A. Ahamburger said:

This is.... interesting? Cooler With Ebola-tainted Blood Stolen in Guinea

 Greetings, Aham .... 

I saw that article!   I thought while reading it that it would be an excellent method for spreading EBOLA around to uninfected areas like across the Texas/Mexico border

IT IS A VERY DANGEROUS WORLD!

b 

Hey b,

IDK about the TX boarder, but I do know it could spread it further around Africa and the Middle east - hence the reason they are worried.

Something else to take note of.. Keep in mind this was from the start of the month, and since then even the WHO has admitted it's only gotten worse.

‘Entire Villages Disappeared’: Ebola Deaths in Sierra Leone ‘Underreported’

Ebola’s toll on Sierra Leone is much greater than previously thought, with entire villages killed off by the virus. This means up to 20,000 people could have succumbed to the disease by now, a senior coordinator for Doctors Without Borders (MSF) believes.

According to Rony Zachariah, coordinator of operational research for MSF, the Ebola impact on Sierra Leone is in fact “under-reported,” AFP quotes.
“The situation is catastrophic. There are several villages and communities that have been basically wiped out. In one of the villages I went to, there were 40 inhabitants and 39 died,” Zachariah told the agency. “Whole communities have disappeared but many of them are not in the statistics. The situation on the ground is actually much worse.”

I also came across something else that sheds a light on sanitation... San Francisco's public defecation map highlights a shitty situation

[Aman A.K.A. Ahamburger]

Cases continue to mount in Mali - where a civil war is on the very - and according to a Liberian heath worker, cases in rural Liberal are not under control at all. I guess there is a reason for the UN: Deadline to curb Ebola will not be met....

God bless us all,

[dothedd]

EBOLA

Here’s How the Ebola Vaccine Trial Is Doing

Nov. 25, 2014

Kallista Images—Getty Images/Kallista Images
University of Maryland scientists are figuring out what doses of the Ebola vaccine are effective and still safe

Dr. Bruce Ribner.

Meet America’s Top Ebola Doctor
Ebola Should Change How We Fund Drugs for Emerging Disease

Scientists Explore 10,000 Compounds for an Ebola Drug

Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.


Morning Must Reads: November 26
Ebola Isolation Is ‘Pretty Much Vacation’ for U.S. Service Members Back From West Africa
'Tragic Event': Video Shows Cop Shoot 12-Year-Old Within Seconds NBC News
Thanksgiving Storm Threatens Travel Plans for Millions NBC News

University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.

The vaccine has already made it through safety trials conducted by the NIH, as well as trials at the University of Oxford and at Emory University. In the current trial, researchers at Maryland vaccinated 10 volunteers on Nov. 10th and 10 volunteers on Nov. 17th. The university has also vaccinated 80 people in Mali. The volunteers’ blood will be monitored for a year, but researchers are most interested in when the participants hit the 28-days post-vaccination mark. That’s when the body should be at its peak antibody response.
time.com/3604899/ebola-vaccine-trial/

[dothedd]

Nov 25, 2014 1:16:58 GMT -5 Aman A.K.A. Ahamburger said:

Cases continue to mount in Mali - where a civil war is on the very - and according to a Liberian heath worker, cases in rural Liberal are not under control at all. I guess there is a reason for the UN: Deadline to curb Ebola will not be met....

God bless us all,

Cases and Deadlines .... NOT UNDER CONTROL/MET!   

[dothedd]

Number of Ebola cases nears 16,000 as Sierra Leone loses ground: WHO
BY STEPHANIE NEBEHAY
GENEVA Wed Nov 26, 2014 2:45pm EST

www.reuters.com/article/2014/11/26/us-health-ebola-who-idUSKCN0JA1Y720141126

Sierra Leone seeks U.S. military help to fight Ebola
DAKAR Wed Nov 26, 2014 2:50pm EST
www.reuters.com/article/2014/11/26/us-health-ebola-leone-idUSKCN0JA20720141126

U.S. Ebola survivors say thankful for 'second chance'
WASHINGTON Wed Nov 26, 2014 1:45pm EST
www.reuters.com/article/2014/11/26/us-health-ebola-usa-survivors-idUSKCN0JA1YH20141126

[Aman A.K.A. Ahamburger]

The vaccines are great news b

On the other hand, after not even coming close to their targets the UN is now saying there is aHuge risk of spread Really? Wow, there is some profound thoughts there, eh?

[Aman A.K.A. Ahamburger]

More foot in the mouth disease..

Ebola data too poor to measure how many patients in isolation: WHO

The World Health Organization says data from the Ebola outbreak are too poor to measure how many patients have been isolated and how many corpses were safely buried, after saying it was making good progress in those areas.

On Monday, the agency said Liberia and Guinea had met an interim goal of isolating 70 per cent of patients, although Sierra Leone had not.

But a report Wednesday said WHO could draw no conclusions on what percentage of patients are isolated from its data.

[dothedd]

Obama Says Urgency Remains in Responding to Ebola Outbreak 

By Angela Greiling Keane and Mike Dorning - Dec 2, 2014 

President Barack Obama used a visit the federal lab where an Ebola vaccine is being developed to urge quick congressional approval of $6.2 billion in emergency spending to fund treatment and prevention efforts in the U.S. and in Africa.

Obama lauded the work of the National Institutes of Health vaccine research center in Bethesda, Maryland, after results of initial clinical trials on an Ebola vaccine produced immune system response and didn’t raise safety concerns.

The Ebola Scourge

“We cannot beat Ebola without more funding,” he said.

The World Health Organization reported today that there have been 17,111 Ebola cases and 6,055 deaths during the epidemic this year. Nearly all of those have been in Guinea, Liberia and Sierra Leone.

Obama said the U.S. response, which includes research on drugs and the deployment of military personnel to help build treatment centers, train health workers and distribute equipment, is beginning to show results.

The crisis isn’t over, he said, and it demands that the U.S. lead the way to encourage other nations to contribute to efforts in battling the disease.

Even as public attention to the outbreak has waned, stopping the outbreak in Africa must remain a national priority to prevent its spread in the U.S., he said.

“Ebola’s not leading the news right now,” he said. “The urgency remains.”

Funding Support

While some Republican lawmakers have criticized the administration’s Ebola response and urged close scrutiny of how they money is spent, none has publicly opposed the funding. Obama said he was encouraged by the bipartisan support the emergency funding has gained.

Obama’s request includes goals to speed testing of vaccines and drugs overseas. Johnson & Johnson (JNJ), based in New Brunswick, New Jersey, and London-based GlaxoSmithKline Plc (GSK) are working on Ebola vaccines, as are NewLink Genetics Corp. (NLNK) and Novavax Inc. (NVAX)

The funding also will help set up the public health infrastructure to deal with similar outbreaks in the future. A White House fact sheet released earlier today said that while the U.S. is better prepared for a domestic outbreak than it was two months ago, “virtually every initiative under way requires immediate, additional funding to be continued or advanced.”

In the past two months, the U.S. has increased its hospital bed capacity for Ebola patients to 53 beds at 35 hospitals from eight beds at three facilities, according to the White House.

Two people, both of whom contracted the illness in Africa, have died because of the Ebola virus in the U.S. Another eight people, two of whom contracted it in the U.S. while treating a patient, have been treated for Ebola and survived.

[dothedd]

11th Sierra Leonean doctor infected with Ebola 

Posted 3:36 p.m. today 

Updated 3:37 p.m. today 

FREETOWN, SIERRA LEONE — Another Sierra Leonean doctor has become infected with Ebola, as the U.N. health agency said Wednesday that poor data from the outbreak is complicating efforts to measure progress in containing the disease.

Ebola has sickened more than 17,000 people, the majority of those in Guinea, Liberia and Sierra Leone. The disease has exacted a particularly heavy toll on health workers and another tested positive on Tuesday in Sierra Leone. Dr. Dauda Koroma is being treated at a military hospital in the capital, according to Chief Medical Officer Dr. Brima Kargbo.

While the disease is still spreading rapidly in Sierra Leone, health officials have expressed some optimism that the outbreak is stabilizing in Guinea and Liberia. The World Health Organization said Monday that those two countries had met an interim goal to isolate 70 percent of patients and safely bury 70 percent of corpses.

But in a report Wednesday, WHO called into question that progress, saying the data is too poor to draw conclusions.

Inconsistencies in data collection mean "this information is not reliable enough at present to draw any conclusions about isolation," the report said. It added that getting information on safe burials was complicated by the fact that many Ebola deaths go unreported.

In Sierra Leone, unsafe burials are thought to be responsible for 70 percent of new infections, Kargbo told reporters Wednesday.

The WHO report said there are enough isolation beds in each country to handle the reported cases — but often not in the places they're needed. Clinics are fairly well distributed in Liberia, the report said, but less so in Guinea. And Sierra Leone needs many more beds in its capital region.

The nation is also short on health care workers. About 100 more African health care workers are expected soon, said Kargbo.

The African Union has promised to send 1,000 health care workers to the three affected countries by the end of the year, but they have been slow to deploy. So far, 87 have arrived, but the AU held a send-off ceremony for 250 more from Nigeria on Wednesday.


Read more at www.wral.com/au-250-nigerian-health-workers-to-treat-ebola/14240202/#UKhATLTdxmCJCcKT.99

[dothedd]

10 people being monitored for Ebola in Boston 

MGH patient has malaria, not deadly virus 

Published 6:10 AM EST Dec 04, 2014

BOSTON —A patient first suspected of having Ebola has, instead, tested positive for malaria, as officials continue to monitor several other people for the deadly virus.

The patient at Massachusetts General Hospital was being monitored under federal guidelines after flying into the U.S. from Liberia.

Watch report

The Boston Public Health commission checked in with him daily, and after he reported a fever Tuesday he was taken by ambulance to the hospital.

The patient has malaria but dozens of people in Massachusetts are being monitored for Ebola, and he was among 10 in Boston.

Since October, the city's public health department has actively monitored 35 people. The monitoring includes daily reporting of temperature and possible Ebola symptoms.

Massachusetts General Hospital is one of eight area hospitals working to become designated Ebola treatment centers.

www.wcvb.com/news/10-people-being-monitored-for-ebola-in-boston/30052928

[dothedd]

Obama to get most of $6.2B request to fight Ebola, says senior GOP senator...

WASHINGTON — A senior member of the Senate Appropriations Committee says President Barack Obama will be awarded the bulk of his $6.2 billion request to fight Ebola in Africa.

Sen. Lindsey Graham said Obama won't get the full $1.5 billion for a contingency fund but will get the green light for other portions of the request.

The South Carolina Republican is a lead negotiator on the foreign aid budget as Congress wraps up a $1 trillion-plus spending bill in advance of a likely vote next week.

Obama asked for $2 billion for the U.S. Agency for International Development and $2.4 billion for the Department of Health and Human Services.

The money would help strengthen the public health system in the U.S. and combat the epidemic in West Africa."

Source: ANDREW TAYLOR , Associated Press Updated: December 4, 2014 - 2:35

[dothedd]

U.S. Senate Committee on Appropriations  

Hearing on U.S. Government Response to Ebola Outbreak 

Testimony: Novavax, Inc. 

Wednesday, November 12, 2014  

Chairwoman Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide written testimony on behalf of Novavax, Inc. regarding our efforts to respond to the current Ebola crisis by rapidly advancing the development and production of a promising vaccine candidate.

Novavax is a clinical‐stage biopharmaceutical company based in Maryland, focused on the
discovery, development and commercialization of recombinant nanoparticle vaccines and
adjuvants. Our principal vaccine candidates currently in clinical development include the
world’s most advanced vaccine for respiratory syncytial virus (“RSV”) and vaccines against
seasonal influenza and pandemic influenza, all of which are in Phase 2 clinical trials.

At Novavax, we use our technology to produce vaccine candidates that can rapidly respond to emerging diseases. For example, under our $179 million HHS/BARDA contract, we have
developed and delivered compelling safety and immunogenicity data in humans for vaccines
against two pandemic influenza strains: H5N1 and H7N9. We also have been monitoring other emerging diseases, such as Middle East Respiratory Syndrome (known as “MERS”), a novel coronavirus first identified in September 2012, as well as the recent outbreak of Ebola virus disease in West Africa.

It is worth noting that five (5) strains of Ebola have been identified, and that the strain currently afflicting West Africa is known as the “Guinea strain”, which was identified in August 2014.

With the speed and flexibility of our platform, we have been able to customize our vaccine to
the currently circulating strain. While current publicly known vaccine approaches target earlier strains of the virus, Novavax’ Ebola vaccine candidate is the first, and currently only, reported Ebola vaccine produced using the genetic sequence of the Guinea strain. Our Ebola vaccine has recently been successfully tested in both rodent and rabbit pre‐clinical models.


We have also tested the vaccine with our Matrix‐M™ adjuvant in these same pre‐clinical models, with results showing that Matrix‐M appears to significantly contribute to enhanced immunogenicity and induction of neutralizing antibodies.

Due to the urgent global public health need for an Ebola vaccine, Novavax feels that it
important to further develop our Ebola vaccine candidate. Therefore, we recently publicly
announced our initiation of a non‐human primate study and our expectation to initiate a Phase 1 clinical trial in December 2014 that will evaluate the safety and immunogenicity of our vaccine candidate in ascending doses, with and without our Matrix‐M adjuvant. Subsequent clinical studies will be designed following the data from the non‐human primate study and the Phase 1 clinical trial.

www.appropriations.senate.gov/sites/default/files/hearings/Novavax.pdf

[Aman A.K.A. Ahamburger]

Sad but true, Two Sierra Leone Ebola doctors die in one day

[dothedd]

Video

Ebola Vaccine Trial Will Take Several Months: Fauci
December 05, 2014
Dec. 5 (Bloomberg) –- Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, talks about tests of a possible vaccine for Ebola. Fauci, speaking with Trish Regan...
www.businessweek.com/videos/2014-12-05/ebola-vaccine-trial-will-take-several-months-fauci

UN peacekeeper with Ebola to arrive in Netherlands
December 06, 2014
www.businessweek.com/ap/2014-12-06/un-peacekeeper-with-ebola-to-arrive-in-netherlands

Cured Cuban Ebola patient leaves Swiss hospital
December 06, 2014
BERLIN (AP) — A Swiss hospital says a Cuban doctor whom it successfully treated for Ebola has left Switzerland to be reunited with his family.Felix Baez Sarria contracted Ebola in Sierra...
www.businessweek.com/ap/2014-12-06/cured-cuban-ebola-patient-leaves-swiss-hospital

2 more Sierra Leonean doctors die of Ebola
December 06, 2014
FREETOWN, Sierra Leone (AP) — Two more Sierra Leonean doctors have died from Ebola, further depleting the West African country's ability to respond to the devastating outbreak, health...
www.businessweek.com/ap/2014-12-06/8th-sierra-leonean-doctor-dies-of-ebola

[dothedd]

A MESSAGE FROM THE PRESIDENT

For Immediate Release December 02, 2014 

FACT SHEET: Update on the Ebola Response 

Since the diagnosis of the first Ebola patient in the United States, we have achieved tremendous progress across all elements of the Administration’s whole-of-government response. In an update provided to President Obama today, White House Ebola Response Coordinator Ron Klain reported that America is far more prepared to cope with Ebola domestically, and much farther along in our efforts to squelch the virus at the source than we were just two months ago, thanks to the work of more than a dozen federal agencies involved in the Ebola response.

Specifically, the progress we have achieved domestically in the past two months includes:


CONTINUED ON THE LINK!!!

www.whitehouse.gov/the-press-office/2014/12/02/fact-sheet-update-ebola-response

[dothedd]

Ebola Voucher Bill Clears Senate, on Course to Become Law 

Posted 03 December 2014 

By Alexander Gaffney, RAC 

The US Senate has passed legislation that would overhaul the Neglected Tropical Disease Priority Review Voucher (PRV) system in the hopes of making it more enticing to pharmaceutical companies, and in particular those developing new treatments for the Ebola virus.

S.2917, the Adding Ebola to the FDA Priority Review Voucher Program Act, passed the US Senate by unanimous consent on 2 December 2013.

"Today the Senate took a strong step to support that mission by passing this bipartisan bill to incentivize the development of Ebola treatments and vaccines," Sen. Tom Harkin (D-IA) said in a statement. Sen. Lamar Alexander (R-TN) said he hoped the bill would "one day help lead to a cure" for Ebola.

For a complete explanation of the Ebola voucher reform bill, please see our explainer article here,

The bill now goes to the US House of Representatives, where an identical piece of legislation, H.R. 5729, was introduced on 18 November 2014 and already enjoys bipartisan support. If passed by the House Energy and Commerce Committee and the full House of Representatives, the bill would then be sent to President Barack Obama, who is expected to sign it.

In a blog post in November 2014, Obama's Ebola czar, Ron Klain, called the bill "encouraging" and said it was a welcomed bipartisan effort against the threat of Ebola.

US Senate Statement

Bill Tracker for S.2917

CONTINUED ON THE FOLLOWING LINK: www.raps.org/Regulatory-Focus/News/2014/12/03/20897/Ebola-Voucher-Bill-Clears-Senate-on-Course-to-Become-Law/#sthash.c2XF417c.Jt7XkJJ0.dpuf

[dothedd]

US Government Immunizes Future Manufacturers of Ebola Vaccines from Legal Liability 

09 December 2014 

The US Department of Health and Human Services (DHHS) is providing a gift to manufacturers of prospective vaccines meant to protect patients against the Ebola virus: Protection from legal liability.

In an announcement in the 9 December 2014 edition of the Federal Register, DHHS said it was issuing a new declaration that would "provide liability protection for activities related to Ebola virus disease vaccines consistent with the terms of the declaration."

Protection from legal liability is a major concern for vaccine manufacturers, whose products are administered to a large number of patients of different ages and health statuses. Even remarkably safe products can cause problems in a very small subset of patients, which becomes almost certain to happen when a vaccine is administered to tens of thousands—or even millions—of patients.

For ordinary vaccines, the US government offers legal protection through its National Vaccine Injury Compensation Program (NVICP) and a unique vaccine claims court system, both of which are funded through a tax assessed on vaccines.

For more background on this process, please see our explanation of a piece of vaccine liability legislation passed into law in June 2013.

But in emergency situations, the US government operates on a slightly different system. Under the Public Readiness and Emergency Preparedness (PREP) Act of 2005, DHHS is allowed to declare that a certain product is immune from liability as long as it is administered or used as a medical countermeasure in a specific patient population.

DHHS said it would use this same authority to allow all use of Ebola vaccines—barring, of course, "willful misconduct"—without concern to legal liability.

The liability waiver extends "without geographic limitation," DHHS noted, and is in effect for the next 12 months.

To date, no such vaccine products have been approved or made available for use through the US Food and Drug Administration's (FDA) Emergency Use Authorization (EUA) process, so for now DHHS' declaration seems anticipatory and intended to promote further research and development in this area.

- See more at: www.raps.org/Regulatory-Focus/News/2014/12/09/20947/US-Government-Immunizes-Future-Manufacturers-of-Ebola-Vaccines-from-Legal-Liability/#sthash.UKEgIySp.dpuf

[dothedd]

FOR IMMEDIATE RELEASE 

December 9, 2014 

Contact: HHS Press Office  

202-690-6343 

Secretary Burwell issues declaration under PREP Act to support development of Ebola vaccines
Important step in effort to develop Ebola vaccines to combat current, future outbreaks
Health and Human Services Secretary Sylvia M. Burwell today announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to facilitate the development and availability of experimental Ebola vaccines. This declaration is intended to assist in the global community’s effort to help combat the current epidemic in West Africa and help prevent future outbreaks there.

www.hhs.gov/news/press/2014pres/12/20141209a.html

[dothedd]

Secretary Burwell issues declaration under PREP Act to support development of Ebola vaccines - Important step in effort to develop Ebola vaccines to combat current, future outbreaks...

Health and Human Services Secretary Sylvia M. Burwell today announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to facilitate the development and availability of experimental Ebola vaccines. This declaration is intended to assist in the global community’s effort to help combat the current epidemic in West Africa and help prevent future outbreaks there.


www.hhs.gov/news/press/2014pres/12/20141209a.html

[dothedd]

FOR IMMEDIATE RELEASE 

December 9, 2014 

  

Secretary Burwell issues declaration under PREP Act to support development of Ebola vaccines Important step in effort to develop Ebola vaccines to combat current, future outbreaks Health and Human Services Secretary Sylvia M. Burwell today announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to facilitate the development and availability of experimental Ebola vaccines. This declaration is intended to assist in the global community’s effort to help combat the current epidemic in West Africa and help prevent future outbreaks there.

www.hhs.gov/news/press/2014pres/12/20141209a.html

[Aman A.K.A. Ahamburger]

A year after one single case in rural Guinea sparked this outbreak, Ebola 'flaming strongly' in western Sierra Leone, Guinea's forests, WHO says. To the point that the WHO says, Virus still 'running ahead of us'.

[dothedd]

You will be able to view the event at videocast.nih.gov when the event is live.
Immunology of Protection from Ebola Virus Infection


Air date: Friday, December 12, 2014, 8:00:00 AM
Time displayed is Eastern Time, Washington DC Local
iCalendar: Add event to iCalendar Add an upcoming event to your calendar.
Description: The goal of this workshop, which is co-sponsored by FDA, NIAID, DOD, CDC, and BARDA, is to discuss important aspects of Ebola virus and vaccine immunology in order to inform future clinical, scientific and regulatory decision-making related to vaccines against Ebola.

For more information go to respond.niaid.nih.gov/conferences/Ebola/Pages/Immunology%20of%20Protection%20from%20Ebola%20Virus%20Infection.aspx
Author: NIAID/NIH, FDA, BARDA, DoD, CDC
Runtime: 9 hours, 30 minutes

[dothedd]

Advisory Committee to the Director - December 2014 (Day 2)


ACD full board meeting

For more information go to acd.od.nih.gov

Friday, December 12, 2014 8:00:00 AM

Office of the Director, NIH

Runtime: 5 hours, 45 minutes

This event will be available for on-demand viewing in our Past Events archive as soon as possible, usually within a few days.

[dothedd]

DECEMBER 11–12, 2014

Agenda Day 1(PDF - 25KB)
Agenda Day 2(PDF - 23KB)
Webcast — Day 1
Webcast — Day 2
HeLa
HeLa Genome Data Access Working Group Report (PDF - 202KB)
HeLa Genome Data Access Working Group Presentation (PDF - 272KB)
ACD Working Group on Diversity Report (PDF - 844KB)
Physician Scientist Workforce Implementation Workgroup Presentation (PDF - 383KB)
ACD LT IRP Working Group
ACD Long-Term Intramural Research Program (LT-IRP) Planning Working Group Presentation (PDF - 242KB)
ACD Long-Term Intramural Research Program (LT-IRP) Planning Working Group Report (PDF - 804KB)
ACD Ebola in 2014 (PDF - 9,173KB)
National Children’s Study (NCS) Working Group Report (PDF - 546KB)


acd.od.nih.gov/meetings.htm

[dothedd]

Ebola: 'We Can't Dig Graves Quickly Enough'
Sky News visits a graveyard where 300 babies have been buried in a week as a nearby community is put in quarantine.
18:23, UK,
Tuesday 13 January 2015


Armed soldiers and police stand guard at Sima village just outside Kerry Town to ensure no-one breaches the quarantine.

There is a thin red string that separates the people who could be carrying the deadly Ebola virus.
CONTINUED: 
 news.sky.com/story/1407199/ebola-we-cant-dig-graves-quickly-enough